Novocol Pharma

What Novocol Pharma does

Novocol Pharma is a Canadian pharmaceutical and medicine manufacturing company headquartered in Cambridge, Canada. Founded in 1985 and operating as a privately held for-profit entity, the company has been in continuous operation for approximately 38 years and reports a headcount of 251-500 employees, placing it within the mid-tier of Canadian pharmaceutical manufacturers. Its industry classification explicitly identifies it as a pharmaceutical and medicine manufacturer, but no product portfolio, therapeutic areas, dosage forms, or customer segments are described in the available inputs. Public commercial information is essentially absent: the company website (novocolpharma.com) returned only a verification/loading placeholder page at the time of capture, and no press releases, product catalogs, regulatory filings, partnerships, leadership disclosures, or financial statements were available in the provided source material.

The captured source set is otherwise limited to a single unrelated news article concerning Moderna's mRNA vaccine facility in Canada and empty/null entries across firmographic sub-objects (no customers, no pricing, no distribution channels, no marketing channels, no partnerships, no awards, no patents, no leadership team, no subsidiaries, no M&A history, no funding history, no restructuring events, no product launches). Because no first-party product, technology, or commercial information is available, this description is deliberately restricted to verifiable firmographic facts and explicit acknowledgement of the data gaps. The implied operational posture is that of a stable, established mid-sized Canadian pharma manufacturer whose product mix, end-market exposure, and commercial mechanics are not disclosed within the scope of this analysis.

Note: One third-party news source referenced in the aggregated input concerns Moderna's Canadian mRNA manufacturing facility and is unrelated to Novocol Pharma; it provides no signal for the subject company.

Name

Novocol Pharma

Website

https://novocolpharma.com

Company type

Private

Founded year

1985

Headcount range

251–500 employees

Short description

Novocol Pharma is a privately held Canadian pharmaceutical and medicine manufacturing company, founded in 1985, headquartered in Cambridge, Canada, with a headcount of 251-500 employees serving the pharmaceutical manufacturing sector.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical manufacturing
• Medicine production
• Drug manufacturing
• Contract pharmaceutical services
• Sterile injectables manufacturing

Headquarters

HQ city

Cambridge

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D

Core offering

Novocol Pharma is a pharmaceutical and medicine manufacturing company based in Cambridge, Canada. Founded in 1985, the company operates with 251-500 employees to produce pharmaceutical products for distribution to business customers in the healthcare and life sciences supply chain. The company functions as a private, for-profit manufacturer within the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Products Pharmaceutical and medicine products manufactured by Novocol Pharma for business customers in the healthcare industry. Specific product lines, formulations, or therapeutic areas are not detailed in the available sources.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• PCI Pharma Services: PCI Pharma Services provides contract manufacturing, packaging, and sterile injectable fill-finish services to pharma and biopharma clients. It is a direct CDMO peer focused on injectable drug product manufacturing similar to Novocol's positioning.
• Aenova Group: Aenova is a CDMO providing solid, semi-solid, liquid, and sterile dosage form manufacturing for pharma clients. Comparable to Novocol in offering contract drug product manufacturing including parenteral capabilities.
• Recipharm: Recipharm is a European-headquartered CDMO offering sterile fill-finish, small-molecule drug product manufacturing, and integrated contract services. Comparable to Novocol as a mid-sized CDMO with parenteral manufacturing capabilities.

Broad incumbents

• Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher, operates one of the largest pharmaceutical contract development and manufacturing networks with sterile injectable capabilities. It is comparable to Novocol as a drug product CDMO, though at much greater scale and breadth.
• Becton, Dickinson and Company (BD): BD Pharmaceutical Systems is a leading manufacturer of prefillable syringes and injectable drug delivery systems. Comparable to Novocol as a participant in the injectable pharmaceutical supply chain, though focused on devices rather than drug product manufacturing.
• Catalent: Catalent is one of the largest global CDMOs with significant sterile injectable and fill-finish capabilities. It is comparable to Novocol as a contract manufacturer of injectable pharmaceutical products serving pharma sponsors, though at vastly larger scale.

Emerging players

• West Pharmaceutical Services: West Pharmaceutical Services supplies primary packaging and delivery systems for injectable drugs, including elastomeric components. It overlaps with Novocol's end market of injectable pharmaceutical manufacturing through shared customers and adjacent offerings.
• Schott Pharma: Schott Pharma specializes in primary containment and drug delivery solutions for injectable medicines, including vials, syringes, and cartridges. Adjacent to Novocol's injectable manufacturing business via shared pharma customers.
• Gerresheimer: Gerresheimer manufactures primary packaging (glass vials, syringes, ampoules) and drug delivery devices for injectable therapies. Comparable to Novocol as a supplier into the sterile injectable value chain serving pharma manufacturers.

Regional players

• CMIC CMO USA: CMIC CMO is a Japanese-headquartered CDMO with sterile injectable fill-finish capabilities serving North American clients. Comparable to Novocol as a mid-sized CDMO with injectable manufacturing expertise, though primarily operating in a different regional footprint.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novocol Pharma